Get the Stockscreener App
64.63
1.25%
0.80
After Hours:
64.25
-0.38
-0.59%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $64.63, with a volume of 7.29M.
It is up +1.25% in the last 24 hours and up +6.40% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$63.83
Open:
$63.6
24h Volume:
7.29M
Relative Volume:
0.61
Market Cap:
$132.02B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
18.14
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-0.32%
1M Performance:
+6.40%
6M Performance:
+7.09%
1Y Performance:
+33.42%
1-Day Range:
$63.36
$64.74
1-Week Range:
$63.00
$65.02
52-Week Range:
$42.52
$68.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
64.63 | 130.39B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,183.16 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.37 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.33 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.97 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.97 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - marketwatch.com
Backed by a massive $2.3 billion investment, a brand-new 600,000-square-foot biopharmaceutical manufacturing campus is officially heading to Houston - Secret Houston
Bristol Myers Squibb stock holds in the low $60s as new multiple myeloma drug class debuts - ad-hoc-news.de
Guggenheim reiterates Bristol-Myers Squibb stock rating on Zenbexus - Investing.com
Guggenheim reiterates Bristol-Myers Squibb stock rating on Zenbexus By Investing.com - Investing.com UK
Bristol Myers Squibb Company $BMY Shares Sold by Russell Investments Group Ltd. - MarketBeat
Bristol-Myers Squibb stock holds above $63 as new myeloma drug wins FDA accelerated approval - AD HOC NEWS
Bellars Harris Wealth Management LLC Acquires Shares of 93,578 Bristol Myers Squibb Company $BMY - MarketBeat
Affinity Investment Advisors LLC Acquires 16,827 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock steadies as FDA approval and strong earnings shape outlook - ad-hoc-news.de
Bristol Myers Squibb Company $BMY Holdings Raised by Principal Financial Group Inc. - MarketBeat
KBC Group NV Has $245.71 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment - sahmcapital.com
Meyer Handelman Co. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Acquired by Vontobel Holding Ltd. - MarketBeat
Massachusetts Financial Services Co. MA Sells 102,388 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Commonwealth Retirement Investments LLC Sells 54,306 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
How First CELMoD MRD-Based Approval in Myeloma At Bristol Myers Squibb (BMY) Has Changed Its Investment Story - simplywall.st
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - marketwatch.com
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma - MedCity News
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Can BMY's First CELMoD Approval Support Its Growth Strategy? - TradingView
USFDA Clears Bristol Myers Squibb's Zenbexus Combo for Rare Blood Cancer - Medical Dialogues
Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore - ad-hoc-news.de
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS (iberdomide), its first CELMoD, in multiple myeloma - Dealroom
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - The Motley Fool
Bristol-Myers Can't Duck UMB Suit Targeting Drug Approvals - Law360
WRIGHT INVESTORS SERVICE INC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma - Investing.com
US FDA approves Bristol Myers' blood cancer treatment - Reuters
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma By Investing.com - Investing.com UK
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse - 巴士的報
ZENBEXUS becomes first FDA-approved CELMoD for myeloma - Stock Titan
Bristol-Myers Squibb Sued Over Heart Disease Treatment Patent - Bloomberg Law News
Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Lawsuit against Bristol Myers over delayed cancer drug is revived By Reuters - Investing.com
Bristol-Myers Must Resume Court Fight on Drug Approval Diligence - Bloomberg Law News
Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived - U.S. News Money
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com UK
IMS Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’ - Benzinga
Bristol Myers Squibb stock holds near recent highs as AI drug discovery pact and Houston build-out r - AD HOC NEWS
US FDA approves Bristol Myers' blood cancer treatment | Business Information & News | FE - Westlaw Today
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory - ABC13 Houston
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? - TradingView
Why Bristol Myers Squibb (BMY) Is Back In The Spotlight - simplywall.st
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):